MX2021001612A - Compuestos utiles en terapia del vih. - Google Patents

Compuestos utiles en terapia del vih.

Info

Publication number
MX2021001612A
MX2021001612A MX2021001612A MX2021001612A MX2021001612A MX 2021001612 A MX2021001612 A MX 2021001612A MX 2021001612 A MX2021001612 A MX 2021001612A MX 2021001612 A MX2021001612 A MX 2021001612A MX 2021001612 A MX2021001612 A MX 2021001612A
Authority
MX
Mexico
Prior art keywords
compounds useful
hiv therapy
hiv
compounds
therapy
Prior art date
Application number
MX2021001612A
Other languages
English (en)
Inventor
Emile Johann Velthuisen
David Temelkoff
John Franklin Miller
La Rosa Martha Alicia De
Lita Suwandi
B Narasinhulu Naidu
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2021001612A publication Critical patent/MX2021001612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

La invención se refiere a compuestos de las fórmulas (I), (Ia), (II) y (IIa), sales de los mismos, composiciones farmacéuticas de los mismos, así como procedimientos para tratar o prevenir el VIH en sujetos.
MX2021001612A 2018-08-09 2019-08-08 Compuestos utiles en terapia del vih. MX2021001612A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716494P 2018-08-09 2018-08-09
PCT/IB2019/056761 WO2020031131A1 (en) 2018-08-09 2019-08-08 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
MX2021001612A true MX2021001612A (es) 2021-05-13

Family

ID=68072882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001612A MX2021001612A (es) 2018-08-09 2019-08-08 Compuestos utiles en terapia del vih.

Country Status (15)

Country Link
US (1) US20220117993A1 (es)
EP (1) EP3833437A1 (es)
JP (1) JP2021534112A (es)
KR (1) KR20210044806A (es)
CN (1) CN112789085A (es)
AR (1) AR115936A1 (es)
AU (1) AU2019317810A1 (es)
BR (1) BR112021002169A2 (es)
CA (1) CA3108635A1 (es)
CL (1) CL2021000329A1 (es)
IL (1) IL280660A (es)
MA (1) MA53280A (es)
MX (1) MX2021001612A (es)
TW (1) TW202023650A (es)
WO (1) WO2020031131A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US20220259252A1 (en) * 2019-08-08 2022-08-18 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US11793827B2 (en) * 2021-01-25 2023-10-24 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
BR0208229A (pt) 2001-03-19 2004-03-09 Ono Pharmaceutical Co Composição farmacêutica que compreende, como um ingrediente ativo, pelo menos um derivado de triazaespiro[5.5]-undecano
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EP2155771A4 (en) * 2007-05-14 2012-09-05 Rfs Pharma Llc AZIDO PURINE NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9822138B2 (en) * 2015-08-10 2017-11-21 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
US20190185508A1 (en) * 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP2021534112A (ja) 2021-12-09
KR20210044806A (ko) 2021-04-23
TW202023650A (zh) 2020-07-01
IL280660A (en) 2021-03-25
MA53280A (fr) 2021-11-17
US20220117993A1 (en) 2022-04-21
WO2020031131A1 (en) 2020-02-13
AU2019317810A1 (en) 2021-02-25
CA3108635A1 (en) 2020-02-13
EP3833437A1 (en) 2021-06-16
AR115936A1 (es) 2021-03-17
BR112021002169A2 (pt) 2021-05-04
CN112789085A (zh) 2021-05-11
CL2021000329A1 (es) 2021-09-03

Similar Documents

Publication Publication Date Title
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
CR20210460A (es) Compuestos útiles en la terapia del vih
PH12016502352A1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
MX2018004664A (es) Antagonistas de ep4.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
EA202090270A1 (ru) Новые замещенные производные ксантина
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication